Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zeripatamig · TG-1801, NI-1701

Bispecific antibody · Immune activation, directed at CD19 and CD47 · developed by TG Therapeutics

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Zeripatamig?

Zeripatamig is a bispecific antibody built from two single-chain variable fragments, one binding CD19 on B cells and one binding CD47. By blocking CD47 from engaging SIRPalpha, it promotes macrophage phagocytosis of CD19/CD47-expressing malignant B cells and induces antibody-dependent cellular cytotoxicity. It is studied in B-cell lymphomas and chronic lymphocytic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TG-1801, NI-1701
Drug type
Bispecific antibody
Targets
CD19, CD47, SIRPalpha (SIRPA) (binding partner it blocks)
Mechanism
Immune activation, directed at CD19 and CD47
Pathways
CD47/SIRPalpha signaling, macrophage phagocytosis, calreticulin/LRP pro-phagocytic signaling, antibody-dependent cellular cytotoxicity, T-cell anti-tumor response
Therapy area
Oncology
Developer
TG Therapeutics, Inc.
In trials of
TGTX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
BK3WC9ZP7A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04806035 Phase 1 CLL Terminated TGTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aggressive LymphomaCLLDLBCLFollicular LymphomaIndolent LymphomaMarginal Zone LymphomaMCLMediastinal Large B-cell LymphomaRichter's TransformationSLL

Other drugs acting on CD19 / CD47

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.